IDXX vs. MRNA, IQV, TAK, ALC, GEHC, CNC, HUM, HLN, COR, and DXCM
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Moderna (MRNA), IQVIA (IQV), Takeda Pharmaceutical (TAK), Alcon (ALC), GE HealthCare Technologies (GEHC), Centene (CNC), Humana (HUM), Haleon (HLN), Cencora (COR), and DexCom (DXCM). These companies are all part of the "medical" sector.
IDEXX Laboratories (NASDAQ:IDXX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 2.1% of IDEXX Laboratories shares are owned by insiders. Comparatively, 15.2% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
IDEXX Laboratories has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories has a net margin of 23.08% compared to Moderna's net margin of -68.84%. IDEXX Laboratories' return on equity of 71.66% beat Moderna's return on equity.
IDEXX Laboratories currently has a consensus price target of $591.50, indicating a potential upside of 19.79%. Moderna has a consensus price target of $126.49, indicating a potential upside of 17.24%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities analysts clearly believe IDEXX Laboratories is more favorable than Moderna.
IDEXX Laboratories received 329 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 72.64% of users gave IDEXX Laboratories an outperform vote while only 58.08% of users gave Moderna an outperform vote.
IDEXX Laboratories has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
In the previous week, Moderna had 17 more articles in the media than IDEXX Laboratories. MarketBeat recorded 25 mentions for Moderna and 8 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.06 beat Moderna's score of 0.43 indicating that IDEXX Laboratories is being referred to more favorably in the media.
Summary
IDEXX Laboratories beats Moderna on 13 of the 17 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
